Back to search
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) trials you may qualify forExpanded access may be provided for qualified patients who have limited treatment options and are not eligible for a clinical trial.
The main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
The primary objective of this study is to assess the long-term safety, including pregnancy, infant, and lactation outcomes, of patients with LC-FAOD who are enr…
The primary objective of this study is to evaluate the long-term safety and efficacy of UX007 in participants with LC-FAOD. The secondary objectives of this stu…
The objectives of this study are to characterize the disease impact, the disease management and resource utilization, and provide benefits to the LC-FAOD commun…
The primary objective of the study was to evaluate the impact of UX007 on acute clinical pathophysiology associated with LC-FAOD following 24 weeks of treatment…
The primary objective of the study is to evaluate the clinical outcomes for the trigger event of patients who receive triheptanoin in the emergency Investigatio…